α-lipoic acid prevents non-alcoholic fatty liver disease in OLETF rats

Liver International

Volumn 32, Issue 10, 2012, Pages 1565-1573

  Jung, Tae Sik ^a   Kim, Soo Kyoung ^a   Shin, Hyun Joo ^a   Jeon, Byeong Tak ^a   Hahm, Jong Ryeal ^a   Roh, Gu Seob ^a  

^a Gyeongsang National University School of Medicine   (South Korea)

Author keywords

lipoic acid; Diabetes; Non alcoholic fatty liver disease; Obesity; OLETF

Indexed keywords

4 HYDROXYNONENAL; ACETYL COENZYME A CARBOXYLASE; ADIPONECTIN; BETA ACTIN; BIOLOGICAL MARKER; CHOLESTEROL; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLOOXYGENASE 2; FATTY ACID; GLUCOSE; HEME OXYGENASE 1; HIGH MOBILITY GROUP B1 PROTEIN; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THIOCTIC ACID; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; LIVER PROTECTION; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ACETYL-COA CARBOXYLASE; ADIPONECTIN; ALDEHYDES; ANIMALS; AZO COMPOUNDS; BLOOD GLUCOSE; BLOTTING, WESTERN; CHOLESTEROL; CYCLOOXYGENASE 2; FATTY ACIDS; FATTY LIVER; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GLUCOSE TRANSPORTER TYPE 4; IMMUNITY, INNATE; IMMUNOHISTOCHEMISTRY; INSULIN; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-6; LEPTIN; LIPID PEROXIDATION; LIVER; RATS; RATS, INBRED OLETF; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; THIOCTIC ACID; TOLL-LIKE RECEPTOR 4; TRIGLYCERIDES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84867097988     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02857.x     Document Type: Article

References (40)

1. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
2. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010; 24: 695-708.
3. Palmieri VO, Grattagliano I, Portincasa P, Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006; 136: 3022-6.
4. García-Ruiz C, Colell A, Morales A, Kaplowitz N, Fernández-Checa JC. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: Studies with isolated mitochondria and rat hepatocytes. Mol Pharmacol 1995; 48: 825-34.
5. Yesilova Z, Yaman H, Oktenli C, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2005; 100: 850-5.
6. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. A HMGB1: Endogenous danger signaling. Mol Med 2008; 14: 476-84.
7. Moran TH, Bi S. Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: Developmental aspects. Dev Psychobiol 2006; 48: 360-7.
8. Kawano K, Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41: 1422-8.
9. Yeon JE, Choi KM, Baik SH, et al. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2004; 19: 799-804.
10. Rector RS, Thyfault JP, Morris RT, et al. Daily exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans Tokushima Fatty rats. Am J Physiol Gastrointest Liver Physiol 2008; 294: G619-26.
11. Atmaca G. Antioxidant effects of sulfur-containing amino acids. Yonsei Med J 2004; 45: 776-88.
12. Lee WJ, Song KH, Koh EH, et al. Alpha-lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 2005; 332: 885-91.
13. Song KH, Lee WJ, Koh JM, et al. alpha-Lipoic acid prevents diabetes mellitus in diabetes-prone obese rats. Biochem Biophys Res Commun 2005; 326: 197-202.
14. Smith AR, Shenvi SV, Widlansky M, Suh JH, Hagen TM. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 2004; 11: 1135-46.
15. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001; 120: 1183-92.
16. Franks PW, Brage S, Luan J, et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res 2005; 13: 1476-84.
17. Buechler C, Wanninger J, Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol 2011; 17: 2801-11.
18. Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg 2010; 20: 623-32.
19. Senn JJ, Klover PJ, Nowak IA, Mooney RA. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002; 51: 3391-9.
20. Park KG, Min AK, Koh EH, et al. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology 2008; 48: 1477-86.
21. Lee WJ, Lee IK, Kim HS, et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol 2005; 25: 2488-94.
22. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 2000; 6: 924-8.
23. Konrad D, Somwar R, Sweeney G, et al. The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: Potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes 2001; 50: 1464-71.
24. Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 2002; 16: 663-78.
25. Valdecantos MP, Pérez-Matute P, González-Muniesa P, et al. Lipoic acid administration prevents nonalcoholic steatosis linked to long-term high-fat feeding by modulating mitochondrial function. J Nutr Biochem 2012; doi: 10.1016/j.jnutbio.2011.11.011 [Epub ahead of print].
26. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
27. Min AK, Kim MK, Kim HS, et al. Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Life Sci 2012; 90: 200-5.
28. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis 2009; 41: 615-25.
29. Han D, Handelman G, Marcocci L, et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. BioFactors 1997; 6: 321-38.
30. Ki SH, Kim SG. Phase II enzyme induction by alpha-lipoic acid through phosphatidylinositol 3-kinase-dependent C/EBPs activation. Xenobiotica 2008; 38: 587-604.
31. Bauer I, Vollmar B, Jaeschke H, et al. Transcriptional activation of heme oxygenase-1 and its functional significance in acetaminophen-induced hepatitis and hepatocellular injury in the rat. J Hepatol 2000; 33: 395-406.
32. Amersi F, Buelow R, Kato H, et al. Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest 1999; 104: 1631-9.
33. Farombi EO, Surh YJ. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol 2006; 39: 479-91.
34. Ogborne RM, Rushworth SA, O'Connell MA. Alpha-lipoic acid-induced heme oxygenase-1 expression is mediated by nuclear factor erythroid 2-related factor 2 and p38 mitogen-activated protein kinase in human monocytic cells. Arterioscler Thromb Vasc Biol 2005; 25: 2100-5.
35. Li L, Chen L, Hu L, et al. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 2011; 54: 1620-30.
36. Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-9.
37. Treutiger CJ, Mullins GE, Johansson AS, et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254: 375-85.
38. Cremer DR, Rabeler R, Roberts A, Lynch B. Long-term safety of alpha-lipoic acid (ALA) consumption: A 2-year study. Regul Toxicol Pharmacol 2006; 46: 193-201.
39. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: A 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999; 22: 1296-301.
40. Koh EH, Lee WJ, Lee SA, et al. Effects of alpha-lipoic Acid on body weight in obese subjects. Am J Med. 2011; 124: 85.e1-8.